INSM Insmed announces positive 12-month data from the ongoing open-label extension study of treprostinil palmitil inhalation powder (tpip) i

INSM Insmed announces positive 12-month data from the ongoing open-label extension study of treprostinil palmitil inhalation powder (tpip) in patients with pulmonary arterial hypertension